Skip to main content
SpringerLink
Log in

Potential of Aromatase Inhibitors for Ovulation and Superovulation Induction in Infertile Women

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical mucous adverse effects that could prevent pregnancy in the face of successful ovulation. In addition, there is a significant risk of multiple pregnancies with clomifene compared with natural cycles. These drawbacks are mainly a result of the extended antiestrogenic effect of clomifene as a result of its accumulation in the body (clomifene isomers have a half-life of several days up to few weeks). Because of these problems, we proposed the concept of aromatase inhibition as a new method of ovulation induction that could avoid many of the adverse effects of clomifene.

Over the last few years several published studies, both controlled and noncontrolled, compared clomifene and treatment with aromatase inhibitors (AIs), either alone or in combination with gonadotropins, for ovulation induction or augmentation. These studies found AIs as effective as clomifene in inducing ovulation, with the major advantage of absence of any antiestrogenic adverse effects. Several other major advantages of AIs include the lower serum estrogen production per developing follicle resulting in more physiological estrogen levels around the time of ovulation and good pregnancy rates with a lower incidence of multiple pregnancy than with clomifene. When combined with gonadotropins for assisted reproductive technologies, AIs reduce the dose of gonadotropins required for optimal follicle recruitment and improve the response to gonadotropin stimulation in poor responders. Such preliminary evidence suggests that AIs may replace clomifene in the future because of similar efficacy with a reduced adverse-effect profile. However, we believe that definitive studies in the form of randomised controlled trials comparing clomifene with AIs are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Table III

Similar content being viewed by others

References

  1. Greenblatt RB, Barfield WE, Jungck EC, et al. Induction of ovulation with MRL/41. JAMA 1961; 178: 101–5

    Article  PubMed  CAS  Google Scholar 

  2. Mitwally MFM, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol 2000; 10: 244–7

    CAS  Google Scholar 

  3. Mitwally MFM, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor re-sponders. Fertil Steril 2002; 774: 776–80

    Article  Google Scholar 

  4. Mitwally MF, Casper RF. Aromatase inhibition reduces gona-dotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003; 188: 1588–97

    Article  Google Scholar 

  5. Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 2004; 11: 406–15

    Article  PubMed  CAS  Google Scholar 

  6. Mitwally MFM, Casper RF. Single dose administration of the aromatase inhibitor, letrozole: a simple and convenient effective method of ovulation induction. Fertil Steril 2005; 83: 229–31

    Article  PubMed  CAS  Google Scholar 

  7. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005; 192: 381–6

    Article  PubMed  CAS  Google Scholar 

  8. Sammour A, Biljan MM, Tan SL, et al. Prospective randomized trial comparing the effects of letrazole (LE) and clomiphene citrate (CC) on follicular development, endometrial thickness and pregnancy rate in patients undergoing super-ovulation prior to intrauterine insemination (IUI). Fertil Steril 2001; 76: S110

    Article  Google Scholar 

  9. Fatemi HM, Kolibianakis E, Tournaye H, et al. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online 2003; 75: 543–6

    Article  Google Scholar 

  10. Healey S, Tan SL, Tulandi T, et al. Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertil Steril 2003; 806: 1325–9

    Article  Google Scholar 

  11. Al-Fadhli R, Sylvestre C, Buckett W, et al. A randomized trial of superovulation with two different doses of letrozole. Fertil Steril 2006; 85: 161–4

    Article  PubMed  CAS  Google Scholar 

  12. Al-Omari WR, Sulaiman WR, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2004; 853: 289–91

    Article  Google Scholar 

  13. Al-Fozan H, Al-Khadouri M, Tan SL, et al. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004; 82: 1561–3

    Article  PubMed  CAS  Google Scholar 

  14. Goswami SK, Das T, Chattopadhyay R, et al. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod 2004; 19: 2031–5

    Article  PubMed  CAS  Google Scholar 

  15. Cortinez A, De Carvalho I, Vantman D, et al. Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients. Fertil Steril 2005; 83: 110–5

    Article  PubMed  CAS  Google Scholar 

  16. Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 4347–53

    Article  PubMed  CAS  Google Scholar 

  17. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005; 23: 3858–9

    Article  PubMed  Google Scholar 

  18. Garcia-Velasco JA, Moreno L, Pacheco A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005; 84: 82–7

    Article  PubMed  CAS  Google Scholar 

  19. Ryan GL, Moss V, Davis WA, et al. Oral ovulation induction agents combined with low-dose gonadotropin injections and intrauterine insemination: cost- and clinical effectiveness. J Reprod Med 2005; 50: 943–50

    PubMed  CAS  Google Scholar 

  20. Bayar U, Tanrierdi HA, Barut A, et al. Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertil Steril 2006; 85: 1045–8

    CAS  Google Scholar 

  21. Elnashar A, Fouad H, Eldosoky M, et al. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril 2006; 85: 161–4

    Article  Google Scholar 

  22. Atay V, Cam C, Muhcu M, et al. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res 2006; 34: 73–6

    PubMed  CAS  Google Scholar 

  23. Sohrabvand F, Ansari S, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod 2006; 21: 1432–5

    Article  PubMed  CAS  Google Scholar 

  24. Cole PA, Robinson CH. Mechanism and inhibition of cyto-chrome P-450 aromatase. J Med Chem 1999; 33: 2933–44

    Article  Google Scholar 

  25. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620–35

    PubMed  CAS  Google Scholar 

  26. Mauras N, Lima J, Patel D, et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemes-tane), in young males. J Clin Endocrinol Metab 2003; 88: 5951–6

    Article  PubMed  CAS  Google Scholar 

  27. Mitwally MFM, Casper RF. Aromatase inhibition for ovarian stimulation: future avenues for infertility management. Curr Opin Obstet Gynecol. 2002; 14: 255–63

    Article  PubMed  Google Scholar 

  28. Mitwally MFM, Casper RF. Aromatase inhibitors for the treatment of infertility. Expert Opin Investig Drugs. 2003; 12: 353–71

    Article  PubMed  CAS  Google Scholar 

  29. Mitwally MFM, Casper RF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2006; 91: 760–71

    PubMed  Google Scholar 

  30. Naftolin F, MacLusky NJ, Leranth CZ, et al. The cellular effects of estrogens on neuroendocrine tissues. J Steroid Biochem 1988; 30: 195–07

    Article  PubMed  CAS  Google Scholar 

  31. Roberts V, Meunier H, Vaughan J, et al. Production and regulation of inhibin subunits in pituitary gonadotropes. Endocrinology 1989; 124: 552–4

    Article  PubMed  CAS  Google Scholar 

  32. Mason AJ, Berkemeier LM, Schmelzer CH, et al. Activin B: precursor sequences, genomic structure and in vitro activities. Mol Endocrinol 1989; 3: 1352–8

    Article  PubMed  CAS  Google Scholar 

  33. Mitwally MFM, Casper RF. Letrozole for ovulation induction. Exp Rev Obstet Gynecol 2006; 1(1): 15–27

    Article  CAS  Google Scholar 

  34. Weil SJ, Vendola K, Zhou J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 1989; 837: 2479–85

    Google Scholar 

  35. Weil S, Vendola K, Zhou J, et al. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999; 848: 2951–6

    Article  Google Scholar 

  36. Vendola KA, Zhou J, Adesanya OO, et al. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998; 101: 2622–9

    Article  PubMed  CAS  Google Scholar 

  37. Vendola K, Zhou J, Wang J, et al. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol Reprod 1999; 612: 353–7

    Article  Google Scholar 

  38. Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992; 13: 641–69

    PubMed  CAS  Google Scholar 

  39. Mitwally MFM, Casper RF, Diamond MP. The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment. Reprod Biol Endocrinol 2005; 4: 3–54

    Google Scholar 

  40. Hamilton A, Piccart M. The third-generation nonsteroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999; 10: 377–84

    Article  PubMed  CAS  Google Scholar 

  41. Goss PE. Risks versus benefits in the clinical application of aromatase inhibitors. Endocr Relat Cancer 1999; 6: 325–32

    Article  PubMed  CAS  Google Scholar 

  42. Palter SF, Tavares AB, Hourvitz A, et al. Are estrogens of import to primate/human ovarian folliculogenesis? Endocr Rev 2001; 223: 389–424

    Article  Google Scholar 

  43. Tiboni GM. Aromatase inhibitors and teratogenesis. Fertil Steril 2004; 81: 1158–9

    Article  PubMed  Google Scholar 

  44. Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins [abstract no. 1033]. Fertil Steril 2005; 84 Suppl. 1: 231

    Article  Google Scholar 

  45. Tulandi T, Al-Fadhli R, Kabli N, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006; 85: 1761–5

    Article  PubMed  CAS  Google Scholar 

  46. Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995; 16: 103–13

    Article  CAS  Google Scholar 

  47. Tredway DR, Buraglio M, Hemsey G, et al. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers. Fertil Steril 2004; 82: 1587–93

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Supported in part by grants from the Canadian Institutes of Health Research, Ottawa, Ontario, Canada. Drs Mitwally and Casper have patent applications for use of aromatase inhibitors for ovulation induction and a licensing agreement with Serono for commercialisation of aromatase inhibitors for ovulation induction.

Author information

Authors and Affiliations

  1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, New Mexico, USA

    Mohamed F. M. Mitwally

  2. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan, USA

    Mohamed F. M. Mitwally

  3. Division of Reproductive Sciences, Fran and Lawrence Bloomberg Department of Obstetrics and Gynecology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital and The University of Toronto, 150 Bloor St West, Suite 210, Toronto, Ontario, M5S 2X9, Canada

    Robert F. Casper

Authors
  1. Mohamed F. M. Mitwally
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert F. Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert F. Casper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitwally, M.F.M., Casper, R.F. Potential of Aromatase Inhibitors for Ovulation and Superovulation Induction in Infertile Women. Drugs 66, 2149–2160 (2006). https://doi.org/10.2165/00003495-200666170-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666170-00001

Keywords

Search

Navigation